Professional area
Everything this site offers to ophthalmologists, residents and researchers, gathered here. Courses are free and bilingual; only the ADC tool's summary tables require registration, which is free.
Tools New
Decision support at the bedside, and a worksheet to fill in at the slit lamp.
Twenty-two molecules grouped by payload. For each: target, linker, expected ocular effects and management — prophylaxis, monitoring, treatment, chemotherapy modulation. Assisted CTCAE grading.
Courses
Ordered from general to specialised: the first lays the groundwork, the others build on it.
The foundation
Read this first. The physiology of repair, on which everything else builds.
1Corneal wound healingStart here4 pages
The general course. Epithelial and stromal repair, basement membrane, EMMPRIN/CD147, myofibroblasts, angiogenic privilege and neovascularisation.
The mechanisms
What happens at cell and molecular level when repair goes wrong.
2Direct epithelial–stromal interactions3 pages
What happens when the anatomical barriers give way: persistent epithelial defect, MMP amplification loop, and the two outcomes — fibrosis or stromal melting.
3Corneal macrophages3 pages
Corneal immune privilege, resident and recruited populations, M1/M2 polarisation, NLRP3, MIF, TGF-β and their share in fibrosis.
Clinical situations
Three entities where those mechanisms become a decision at the bedside.
4Neurotrophic keratitis3 pages
Corneal innervation and trophic function, pre- versus post-ganglionic distinction, Mackie classification, treatments (RGTA, recombinant NGF).
5Topical NSAIDs & healing5 pages
NSAID keratolysis: landmark series, refutation of the excipient hypothesis, the COX pathway and the 12-HHT/BLT2 mediator, at-risk patients, practical management.
- The two-hit model
- The 1998-1999 US outbreak
- The landmark series
- The signal by molecule
- Surgical contexts
- Incidence: the methodological void
- The 1999-2002 reasoning
- Compared formulations
- The facts that refute the hypothesis
- The topographic argument
- TPGS: a vehicle, not a toxin
- COX-1 and COX-2 in the cornea
- PGE2 is not the driver
- 12-HHT and the BLT2 receptor
- Lipid signals of repair
- Aspirin, non-acetylating NSAIDs and coxibs
- MMP, TIMP and the epithelial-stromal interface
- EMMPRIN/CD147, the control point
- Induced corneal hypoaesthesia
- Ranked mechanisms
- At-risk patients
- Before prescribing
- During treatment
- Facing suspected keratolysis
- References
6Ocular toxicity of ADCsNew7 pages
Antibody–drug conjugates: payloads, linker chemistry, corneal phenotypes, molecule-by-molecule epidemiology, prevention and chemotherapy modulation.
- Introduction
- ADC architecture and pharmacology
- Pathophysiology of ocular toxicity
- Why the cornea and the limbus?
- Corneal clinical phenotypes
- Non-corneal involvement
- Differential diagnosis
- Epidemiology by molecule
- CTCAE grading
- Prevention
- Monitoring the symptomatic patient
- ADC-specific management
- Dose modification and the oncological stake
- Quality of life
- Recommendations and perspectives
- Key points
- References
Review
One long review, split into sheets you can read separately.
Comprehensive review of therapeutic agents, one sheet per agent: growth factors and blood derivatives, amniotic membrane and RGTA, anti-MMP agents, surgical adjuvants, negative modulators (BAK, corticosteroids), cell and gene therapies. Evidence level and regulatory availability for each.
Patient pages
To hand out or point your patients to.